Posted on 25th November 2014
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
29th December 2018
An Officer of the Order of the British Empire (OBE) medal has been awarded to Donald Cameron in the Queen’s New Year Honours List 2019. The award recognises the practice's former managing director's...Read more
05th December 2018
Last month we welcomed parents of children with congenital cataracts to a coffee morning to meet others in a similar position and to discuss any concerns with our optometrists. We are also setting up ...Read more